Pricing and Reimbursement

OHE has just published two new briefings entitled ‘New Age Decision Making in HTA’ and ‘How Can HTA in Asia-Pacific Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?’. Both publications are reports of panel sessions held at the HTAi 2016 meeting in Tokyo.

The biannual EuHEA Conference was held at the Hamburg Center for Health Economics (HCHE), 13-16th July 2016. The topic of the meeting was “Know the Ropes - Balancing Costs and Quality in Health Care”. Members of the OHE team attended and contributed to the conference; this post summarises their activity.

“Complementary diagnostics” are defined as tests using biomarkers for risk assessment, diagnosis, prognosis, monitoring, and guiding therapeutic decisions. This White Paper presents a more comprehensive framework for considering their value contribution.

This is part one of two posts containing posters and presentations by members of the OHE team at ISPOR’s 21st Annual International Meeting held in Washington DC, 20-25th May 2016.

This post contains posters which were presented by members of the OHE team at the 2016 HTAi Annual Meeting held in Tokyo, Japan, 10-14 May.

The 2016 HTAi Annual Meeting was held in Tokyo, Japan, 10-14 May 2016. The focus of the meeting was Informing Health Care Decisions with Values and Evidence. This post contains presentations given by the OHE team.

ISPOR’s 21st Annual International Meeting is scheduled for 20-25th May 2016 in Washington DC. Several members of the OHE team will be attending and disseminating important research.

Martina Garau presented at the last ISPOR Italy Chapter – Rome conference on the topic of economic gains produced by health interventions.

OHE is pleased to be hosting not one, not two but three seminars over the coming weeks.

The blog provides links to slide sets for presentations relating to going ‘beyond QALYs’ when valuing health care interventions, managed entry agreements within the UK pharmaceutical landscape, new business models for antibiotics, and economics of the market for medicines


Subscribe to RSS - Pricing and Reimbursement